A venture capital firm based in Western Europe owns several funds and currently focuses on investments in Europe based diagnostics companies. The firm invests in Europe and North America, and typically allocates about €5 million equity to each portfolio company, generally over several tranches.

The firm invests in therapeutics and diagnostics to treat rare diseases.  The firm is agnostic regarding technologies and indication areas, and typically invests early but is open to companies with assets ranging from preclinical development through Phase II.

The firm prefers to invest in companies that can present an exit opportunity in 3-5 years, usually through a pharmaceutical industry partnership.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com.

An investment firm that represents a high net worth family office has offices in Western Europe. The firm makes equity investments in life science companies, typically at the Series B stage or later; the firm allocates a total of EUR 3-10 million over the life of an investment. The firm invests in Europe and the US.

In the life science sector, the firm invests in medical applications (therapeutics, diagnostics, and medical devices), life science services and tools, and agtech / food tech. For therapeutics companies, the firm only invests in companies with assets that have obtained data from in-human clinical trials (at minimum, human safety data is required). For medtech or diagnostic companies, the product must be no more than 1 year from commercialization. The firm invests broadly in the life science field, but has a specific interest in technologies at the intersection between the healthcare and food industries, including nutraceuticals and the microbiome.

The firm is a hands-on investor that prefers to take a board seat and work closely with management, and therefore prefers to invest in companies located close to their offices. The firm prefers to invest as part of a strong syndicate that includes experienced investors with whom the firm has pre-existing connections.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com.

A family investment group based in the USA is looking to invest in technologies related to ophthalmology and oncology that are in the pre-clinical to Ph I stages. The firm will invest in seed and series A rounds up to $10M. The firm is willing to invest globally, with a special interest in companies based in North America, Europe and China.

The firm is interested in therapeutics, medical device and diagnostics companies with technologies in the ophthalmology and oncology spaces. The firm may consider digital health companies as well. For ophthalmology-related companies, Halcyon is most interested in small molecules or combination devices. For oncology-related companies, the firm prefers I/O technologies or diagnostics.

The firm prefers to take a board seat after investing.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com.

A venture capital arm of a large Asian financial conglomerate mainly invests in the IT, communications, cultural/creative, alternative energies, biotechnology, and medical/healthcare sectors. The firm seeks to invest in commercial stage or expansion phase companies that are 3-5 years from IPO. Typical equity allocations range from US$1-3 million and can be up to US$5 million. The firm is now focused on China and South East Asia, with interest in opportunities from North America and Europe to a lesser extent.

Within healthcare, the firm is interested in all sectors of medical technology, including consumer and non-consumer products. The firm is agnostic to indications. The firm is less interested in therapeutics, but it would consider drug reformulation. The firm looks for products that are ready for commercialization or at the commercial stage and seeking growth/expansion capital.

The firm looks for a strong and experienced management team.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com.

An investment group based out of the USA is a wholly owned subsidiary of a large healthcare system. The firm engages in strategic investments across a wide variety of sectors to benefit the health system. The firm invests at a set pace with ~2 surgery centers being invested in per year and are currently looking to diversify their portfolio. The firm tends to invest in seed and pre-revenue rounds as their allocation size is on the smaller side, but is interested in revenue generating opportunities with smaller rounds.

The firm is particularly interested in technologies that can help them increase the quality of care, decrease the cost of care, and increase the access of services to populations which have been historically denied. Beyond that though, the firm is rather opportunistic within the healthcare IT, medical devices, healthcare services, and care delivery spaces and currently has no specific focus.

The firm requires that companies have some sort of relationship with the firm or have the endorsement of the senior management of the health system.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com.

A pharmaceutical company headquartered in Asia operating globally in terms of R&D, manufacturing, distribution and marketing, with a strong focus on prescription medicines. The firm’s corporate investment arm has offices in USA and Japan and actively makes strategic equity investments in early-stage companies that align with the firm’s business. The firm will invest between $1-5M in seed to mid-stage companies, with Series A being the sweet spot. The firm is open to global opportunities.

The firm is interested in opportunities that are synergistic with their research and development pipeline in neurology and oncology. The firm is interested in pharmaceutical drugs across various modalities, including but not limited to antibodies, peptides, nucleic acids, and cell/gene therapy. The firm is also interested in digital therapeutics, IT solutions, and diagnostics. Within neurology, the firm is strongly interested in (but not limited to) neurodegenerative diseases including Alzheimer’s Disease and Parkinson’s Disease as well as epilepsy and sleep disorders. Within oncology, the firm is interested in solid tumors (breast, liver, lung, etc).

The firm is a flexible investor and can act as a lead or follow-on investor. The corporate venture investment closely collaborates with the firm’s business development division and leverages its global network of pharmaceuticals, research universities, etc. to identify and collaborate with cutting edge opportunities.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com.

A life sciences venture capital fund with offices in Asia currently manages two funds and is actively seeking investment opportunities. On average, the size of investment is $5-25M in venture rounds. The firm prefers to act as the lead investor but is also open to co-investing. The firm looks for companies located around the globe, with a preference in the US and China. The firm is actively seeking new investment opportunities.

The firm is focused on Therapeutics and Medical Devices opportunities. The firm’s core focused therapeutic areas include oncology, immunology and CNS diseases, but is also opportunistic in other indications (modality agnostic) and willing to consider orphan indications. The firm is also interested in interventional, novel medical devices in cardiovascular, neuro-vascular diseases.

The firm prefers management team with strong scientific background and expertise, successful track records would be a plus but is not required. The firm generally takes a board seat.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com.